about
Injury induces localized airway increases in pro-inflammatory cytokines in humans and mice.Novel association of the R230C variant of the ABCA1 gene with high triglyceride levels and low high-density lipoprotein cholesterol levels in Mexican school-age children with high prevalence of obesity.Parenteral nutrition maintains pulmonary IgA antibody transport capacity, but not active transport, following injury.Effects of sterculic acid on stearoyl-CoA desaturase in differentiating 3T3-L1 adipocytes.Molecular differences caused by differentiation of 3T3-L1 preadipocytes in the presence of either dehydroepiandrosterone (DHEA) or 7-oxo-DHEA.Redox reactions of dehydroepiandrosterone and its metabolites in differentiating 3T3-L1 adipocytes: A liquid chromatographic-mass spectrometric study.Injury stimulates an innate respiratory immunoglobulin a immune response in humans.Parenteral nutrition and fasting reduces mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) mRNA in Peyer's patches of mice.Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis.Phenolic Compounds in Organic and Aqueous Extracts from Pods Analyzed by ULPS-ESI-Q-oa/TOF-MS. In Vitro Antioxidant Activity and Anti-Inflammatory Response in CD-1 MiceDetection and recognition thresholds to the 4 basic tastes in Mexican patients with primary Sjögren's syndromeParenteral nutrition impairs gut-associated lymphoid tissue and mucosal immunity by reducing lymphotoxin Beta receptor expressionDecreased enteral stimulation alters mucosal immune chemokinesIntestinal polymeric immunoglobulin receptor is affected by type and route of nutritionEffects of lymphotoxin beta receptor blockade on intestinal mucosal immunityParenteral nutrition inhibits tumor necrosis factor-alpha-mediated IgA response to injuryEnteral feeding of a chemically defined diet preserves pulmonary immunity but not intestinal immunity: the role of lymphotoxin beta receptorCholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial
P50
Q34724327-F462D7D2-2257-4C91-8020-CA9A565A4BB9Q40303801-29BC8B01-608C-4BBE-989E-988BDA488FDFQ41906828-D7B1C880-3D3F-4C5A-BCB0-0DB5DD4E45C0Q42806962-44D5CB32-ACA6-4069-9BD6-3553D7F5A015Q42816098-A846C921-6ACC-4DAC-91FA-AB994B280FFBQ42834085-AA228756-CEAF-4AC2-8F07-E2E47EBE3484Q46732786-F86BC4F3-291C-4992-8AED-605F874715BBQ51481920-94B29725-E447-4E8E-BB51-95C17E69F03FQ53378011-FFD06210-07A6-4A15-A1B5-553CF7AF8CB8Q58691371-B7FC84EE-0493-47D2-A355-54347BE74811Q79820833-9F94714D-FB3C-4BC9-8487-249FBCE0BB94Q80154238-09F47EDB-05ED-4A5F-BF0F-D9BA2D1B4A31Q80423564-03400E6B-9239-498F-9F88-F1F1514DD92EQ80825852-FDD31F4D-31DA-4247-8934-A248BE1D6682Q80825856-3C923F4C-6275-49BE-B413-8C73D9717173Q80946446-EA4B04B0-0AFD-4DFC-BACC-4C1D7703C7C3Q81464154-32DE6290-819B-42B6-B345-736E6AD560F1Q92475570-5F47DF4E-6C5F-46B2-A285-289D09FEB5F2
P50
description
researcher
@en
name
F Enrique Gomez
@en
F Enrique Gomez
@nl
type
label
F Enrique Gomez
@en
F Enrique Gomez
@nl
prefLabel
F Enrique Gomez
@en
F Enrique Gomez
@nl
P106
P31
P496
0000-0002-5638-6710